190 related articles for article (PubMed ID: 25194640)
1. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Zauderer MG; Drilon A; Kadota K; Huberman K; Sima CS; Bergagnini I; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Riely GJ; Kris MG; Krug LM; Pietanza MC
Lung Cancer; 2014 Nov; 86(2):237-40. PubMed ID: 25194640
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
[TBL] [Abstract][Full Text] [Related]
3. O
Hiddinga BI; Pauwels P; Janssens A; van Meerbeeck JP
Lung Cancer; 2017 May; 107():91-99. PubMed ID: 27492578
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
[TBL] [Abstract][Full Text] [Related]
7. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Makino K; Nakamura H; Hide T; Kuratsu J
J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
[TBL] [Abstract][Full Text] [Related]
8. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
10. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
Jiang X; Reardon DA; Desjardins A; Vredenburgh JJ; Quinn JA; Austin AD; Herndon JE; McLendon RE; Friedman HS
J Neurooncol; 2013 Aug; 114(1):135-40. PubMed ID: 23686298
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Pietanza MC; Waqar SN; Krug LM; Dowlati A; Hann CL; Chiappori A; Owonikoko TK; Woo KM; Cardnell RJ; Fujimoto J; Long L; Diao L; Wang J; Bensman Y; Hurtado B; de Groot P; Sulman EP; Wistuba II; Chen A; Fleisher M; Heymach JV; Kris MG; Rudin CM; Byers LA
J Clin Oncol; 2018 Aug; 36(23):2386-2394. PubMed ID: 29906251
[TBL] [Abstract][Full Text] [Related]
12. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
13. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Horton TM; Thompson PA; Berg SL; Adamson PC; Ingle AM; Dolan ME; Delaney SM; Hedge M; Weiss HL; Wu MF; Blaney SM;
J Clin Oncol; 2007 Nov; 25(31):4922-8. PubMed ID: 17971589
[TBL] [Abstract][Full Text] [Related]
15. Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Miglio U; Mezzapelle R; Paganotti A; Veggiani C; Mercalli F; Mancuso G; Gaudino E; Rena O; Buosi R; Boldorini R
Diagn Cytopathol; 2015 Nov; 43(11):947-52. PubMed ID: 26152836
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
17. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
19. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
